» Articles » PMID: 3513169

Inhibition of Tumor-cell-mediated Extracellular Matrix Destruction by a Fibroblast Proteinase Inhibitor, Protease Nexin I

Overview
Specialty Science
Date 1986 Feb 1
PMID 3513169
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Human fibrosarcoma (HT-1080) cells, in contrast to normal fibroblasts, rapidly hydrolyze the glycoprotein, collagen, and elastin extracellular matrix (ECM) synthesized by cultured rat aortic smooth muscle cells. This degradation occurs at a rapid rate in the presence of serum, indicating that the cellular proteases responsible are relatively insensitive to serum proteinase inhibitors. Here it is shown that protease nexin I (PNI), a fibroblast-secreted inhibitor of urokinase, plasmin, and certain other serine proteinases, effectively inhibited the HT-1080 cell-mediated degradation of this ECM. PNI at 2.0 nM significantly inhibited matrix destruction for 1-2 days and at 0.2 microM caused a virtually complete inhibition that persisted for the entire 10-day period of observation. Inhibition of ECM destruction was accompanied by a transient arrest of HT-1080 cell proliferation that took place during the first 3 days after PNI addition. PNI did not inhibit the growth of normal fibroblasts and also did not inhibit the growth of HT-1080 cells that were seeded onto plastic dishes rather than onto ECM. Like many types of malignant cells, HT-1080 cells release large amounts of urokinase. Antibody against this plasminogen activator partially protected ECM from HT-1080 cell-mediated hydrolysis, indicating that it may have been a target of PNI. One potential physiological function of PNI could be to help maintain the integrity of connective tissue matrices, protection that malignant cells could overcome by secreting proteinases in excessive amounts.

Citing Articles

An expanded analysis framework for multivariate GWAS connects inflammatory biomarkers to functional variants and disease.

Ruotsalainen S, Partanen J, Cichonska A, Lin J, Benner C, Surakka I Eur J Hum Genet. 2020; 29(2):309-324.

PMID: 33110245 PMC: 7868371. DOI: 10.1038/s41431-020-00730-8.


Collagen I: a kingpin for rotator cuff tendon pathology.

Thankam F, Dilisio M, Gross R, Agrawal D Am J Transl Res. 2019; 10(11):3291-3309.

PMID: 30662587 PMC: 6291732.


Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.

Madureira P, Bharadwaj A, Bydoun M, Garant K, OConnell P, Lee P Oncotarget. 2016; 7(30):47720-47737.

PMID: 27351226 PMC: 5216974. DOI: 10.18632/oncotarget.10279.


Association of SERPINE2 gene with the risk of chronic obstructive pulmonary disease and spirometric phenotypes in northern Han Chinese population.

An L, Yang T, Zhang Y, Lin Y, Zhang H, Jiao X Mol Biol Rep. 2011; 39(2):1427-33.

PMID: 21611750 DOI: 10.1007/s11033-011-0877-0.


Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.

Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P J Clin Oncol. 2007; 25(7):773-80.

PMID: 17327601 PMC: 2257989. DOI: 10.1200/JCO.2006.07.4187.


References
1.
Deutsch D, MERTZ E . Plasminogen: purification from human plasma by affinity chromatography. Science. 1970; 170(3962):1095-6. DOI: 10.1126/science.170.3962.1095. View

2.
Scott R, Bergman B, Bajpai A, HERSH R, Rodriguez H, Jones B . Protease nexin. Properties and a modified purification procedure. J Biol Chem. 1985; 260(11):7029-34. View

3.
Jones P, DeClerck Y . Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells. Cancer Res. 1980; 40(9):3222-7. View

4.
Wilson E, Becker M, Hoal E, DOWDLE E . Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Cancer Res. 1980; 40(3):933-8. View

5.
Wun T, OSSOWSKI L, Reich E . A proenzyme form of human urokinase. J Biol Chem. 1982; 257(12):7262-8. View